We are monitoring the impact of COVID-19 & Recession alarm on APAC Kidney Cancer Diagnostics and Therapeutics Market Get in touch with us for detailed analysis Know More
Share on

Asia Pacific Kidney Cancer Diagnostics and Therapeutics Market Research Report - Segmented By Type, Tests & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends & Forecasts (2022 to 2027)

Published: January, 2022
ID: 788
Pages: 138

APAC Kidney Cancer Diagnostics and Therapeutics Market Size (2022 to 2027)

The size of the Kidney Cancer Diagnostics and Therapeutics Market in Asia-Pacific was worth USD 1.00 billion in 2022 and estimated to be growing at a CAGR of 5.92%, to reach USD 1.33 billion by 2027.

Asia-Pacific is expected to be the fastest-growing regional market worldwide during the forecast period. The expansion of this market is likely to be fueled by an increase in the number of patients who have renal cancer, increased patient awareness, and decreased drug production costs. In addition, increased government activities and other private organizations raising awareness about early cancer detection and prevention are expected to drive market expansion during the forecast period. Furthermore, cancer cells that help them grow, divide and spread are targeted by targeted therapy.

Cabozantinib, axitinib, sunitinib, sorafenib, and pazopanib are targeted medicines used to treat clear cell renal cancer. As a result of the disease's high prevalence and the availability of diagnostic tools and treatment options, the market is predicted to increase. The main drivers driving the growth of the Asia Pacific kidney cancer diagnostic and therapeutics market are the increasing prevalence of kidney cancer, changes in lifestyles such as smoking and drinking, decreased physical activity, and the approval of novel medications to treat kidney cancer. Furthermore, immunotherapies would emerge as a business potential for marketers.

The APAC kidney cancer market is predicted to increase due to continuous technological advancement and drug expansion in various therapies such as immunotherapy and chemotherapy. Immunotherapy is less harmful than chemotherapy, making it more acceptable for the elderly. In comparison to chemotherapy, immunotherapy produces a rapid and consistent response. Therefore, many unidentified patients in underserved areas certainly generate profitable prospects for market dealers.

However, growing consumer preference for generic medications and high costs associated with branded drugs to treat kidney cancer is projected to limit market expansion during the forecast period.

This research report on the APAC kidney cancer diagnostics and therapeutics market has been segmented and sub-segmented into the following categories:

By Type:

  • Transitional Cell Cancer
  • Renal Cell Carcinoma
  • Renal Sarcoma
  • Others

By Tests:

  • Biopsy
  • CT Scan
  • Cystoscopy
  • Intravenous Pyelogram
  • Kidney Ultrasound

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Due to an increase in the number of patients with chronic diseases, the frequency of kidney cancer, and an increase in government inventiveness for expanding healthcare facilities in the region, Asia Pacific is predicted to have the fastest revenue growth. According to GLOBOCAN 2018, China and Japan are the two most important nations in Asia for kidney cancer cases. These countries had among the highest rates of kidney cancer in the world. Furthermore, the International Agency for Research on Cancer estimates that 148,947 new kidney cancer cases were diagnosed in Asia in 2018, with a mortality rate of 79,149 cases. With the rising incidence of kidney cancer, future generations will benefit from more accessible, inexpensive, and diagnosis-related kidney cancer treatment. The growth is forecasted to be driven by technological advancements in devices, increased healthcare spending, and increased demand for blood chemistry tests for kidney cancer diagnosis. As a result of the factors, the Asia-Pacific kidney cancer treatments and diagnostics market is predicted to rise significantly over the forecast period. The aging population, poor diet, and obesity contribute to an increase in kidney cancer cases in China. In addition, cigarette smoking is widespread, adding to the country's burden. Rising awareness of kidney cancer detection and treatment and expanding R&D initiatives are expected to drive market growth in the country.

KEY MARKET PLAYERS:

Companies playing a significant role in the APAC kidney cancer diagnostics and therapeutics market profiled in this report are GlaxoSmithKline, Bayer, Pfizer, Sanofi S.A, Hoffmann La Roche, Novartis, and Abbott Laboratories.

1.Introduction                              

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods                       

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By Type                     

                             5.1.1 Transitional Cell Cancer    

                             5.1.2 Renal cell carcinoma         

                             5.1.3 Renal sarcoma     

                             5.1.4 Other Cancers      

              5.2 By Tests                     

                             5.2.1 Biopsy      

                             5.2.2 CT Scan    

                             5.2.3 Cystoscopy            

                             5.2.4 Intravenous pyelogram    

                             5.2.5 Kidney Ultrasound             

6. Geographical Analysis                                         

              6.1 Introduction                           

              6.2 China                         

              6.3 India                          

              6.4 Japan                         

              6.5 South Korea                            

              6.6 Australia                   

7. Pipeline Product Analysis                                    

              7.1 Overview                                 

              7.2 Pipeline Development Landscape                                 

              7.3 Molecular Targets in the Pipeline                                  

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.   

8.Strategic Analysis                                    

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                             8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9.Market Leaders' Analysis                                     

              9.1 GlaxoSmithKline                    

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                             9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 Bayer                         

              9.3 Pfizer                         

              9.4 Sanofi S.A                 

              9.5 Hoffmann La Roche              

              9.6 Novartis                    

              9.7 Abbott Laboratories                            

10.Competitive Landscape                                      

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11.Expert Opinions                                    

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures                           

  1. Asia-Pacific Kidney Cancer Diagnostics and Therapeutics Market By Region, From 2022 - 2027 (USD Billion)
  2. Asia-Pacific Kidney Cancer Diagnostics and Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  3. Asia-Pacific Transitional Cell Cancer Market By Region, From 2022 - 2027 (USD Billion)
  4. Asia-Pacific Renal cell carcinoma Market By Region, From 2022 - 2027 (USD Billion)
  5. Asia-Pacific Renal sarcoma Market By Region, From 2022 - 2027 (USD Billion)
  6. Asia-Pacific Other Kidney Cancers Market By Region, From 2022 - 2027 (USD Billion)
  7. Asia-Pacific Kidney Cancer Diagnostics and Therapeutics Market By Tests, From 2022 - 2027 (USD Billion)
  8. Asia-Pacific Biopsy Market By Region, From 2022 - 2027 (USD Billion)
  9. Asia-Pacific CT Scan Market By Region, From 2022 - 2027 (USD Billion)
  10. Asia-Pacific Cystoscopy Market By Region, From 2022 - 2027 (USD Billion)
  11. Asia-Pacific Intravenous pyelogram Market By Region, From 2022 - 2027 (USD Billion)
  12. Asia-Pacific Kidney Ultrasound Market By Region, From 2022 - 2027 (USD Billion)
  13. China Kidney Cancer Diagnostics and Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  14. China Kidney Cancer Diagnostics and Therapeutics Market By Tests, From 2022 - 2027 (USD Billion)
  15. India Kidney Cancer Diagnostics and Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  16. India Kidney Cancer Diagnostics and Therapeutics Market By Tests, From 2022 - 2027 (USD Billion)
  17. Japan Kidney Cancer Diagnostics and Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  18. Japan Kidney Cancer Diagnostics and Therapeutics Market By Tests, From 2022 - 2027 (USD Billion)
  19. South Korea Kidney Cancer Diagnostics and Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  20. South Korea Kidney Cancer Diagnostics and Therapeutics Market By Tests, From 2022 - 2027 (USD Billion)
  21. Australia Kidney Cancer Diagnostics and Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  22. Australia Kidney Cancer Diagnostics and Therapeutics Market By Tests, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample